| 1.21 0.04 (3.42%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.57 | 1-year : | 1.77 |
| Resists | First : | 1.34 | Second : | 1.51 |
| Pivot price | 1.25 |
|||
| Supports | First : | 1.07 | Second : | 0.89 |
| MAs | MA(5) : | 1.2 |
MA(20) : | 1.23 |
| MA(100) : | 1.4  |
MA(250) : | 1.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.3 |
D(3) : | 21.9 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 3.81 | Low : | 0.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DRIO ] has closed above bottom band by 37.4%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.23 | 1.23 - 1.24 |
| Low: | 1.17 - 1.17 | 1.17 - 1.18 |
| Close: | 1.2 - 1.21 | 1.21 - 1.22 |
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Fri, 26 Jul 2024
DarioHealth (NASDAQ:DRIO) Stock Passes Below Two Hundred Day Moving Average of $1.60 - Defense World
Thu, 18 Jul 2024
DarioHealth (NASDAQ:DRIO) Shares Cross Below 200 Day Moving Average of $1.62 - Defense World
Tue, 16 Jul 2024
Dario Expands GLP-1 Solution Client Base with New Employer Contract - StockTitan
Thu, 16 May 2024
DarioHealth Corp. (NASDAQ:DRIO) Q1 2024 Earnings Call Transcript - Insider Monkey
Wed, 15 May 2024
DarioHealth Reports First Quarter 2024 Financial and Operating Results - PR Newswire
Thu, 18 Apr 2024
Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 30 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 29.9 (%) |
| Shares Short | 1,540 (K) |
| Shares Short P.Month | 1,530 (K) |
| EPS | -1.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.65 |
| Profit Margin | -282.4 % |
| Operating Margin | -310.1 % |
| Return on Assets (ttm) | -31.4 % |
| Return on Equity (ttm) | -71.7 % |
| Qtrly Rev. Growth | -18.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.73 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 1.9 |
| Price to Cash Flow | -0.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|